StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.78−0.48 (-1.22%)

Close on Nov 17, 2026Market cap $3.76BP/E –Yield –

Xenon Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Xenon Pharmaceuticals's total assets was $1.30B at Jun 30, 2026. For fiscal 2025 it was $633.16M, down 20.7% from the year before. Over ten years it grew 25.8% a year on average. The highest annual figure on record is $964.80M in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$633.16M-20.7%
FY2024Dec 31, 2024$798.14M-17.3%
FY2023Dec 31, 2023$964.80M+27.9%
FY2022Dec 31, 2022$754.15M+31.8%
FY2021Dec 31, 2021$572.01M+202.4%
FY2020Dec 31, 2020$189.19M+28.1%
FY2019Dec 31, 2019$147.70M+20.6%
FY2018Dec 31, 2018$122.43M+165.4%
FY2017Dec 31, 2017$46.12M-31.7%
FY2016Dec 31, 2016$67.49M+5.5%
FY2015Dec 31, 2015$63.95M-26.8%
FY2014Dec 31, 2014$87.42M+60.4%
FY2013Dec 31, 2013$54.49M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.30B+92.2%
Q1 FY2026Mar 31, 2026$1.39B+86.6%
Q4 FY2025Dec 31, 2025$633.16M-20.7%
Q3 FY2025Sep 30, 2025$607.84M-27.3%
Q2 FY2025Jun 30, 2025$674.28M-23.7%
Q1 FY2025Mar 31, 2025$743.28M-19.1%
Q4 FY2024Dec 31, 2024$798.14M-17.3%
Q3 FY2024Sep 30, 2024$835.90M+24.6%
Q2 FY2024Jun 30, 2024$884.01M+29.1%
Q1 FY2024Mar 31, 2024$919.02M+27.7%
Q4 FY2023Dec 31, 2023$964.80M+27.9%
Q3 FY2023Sep 30, 2023$671.09M-13.5%
Q2 FY2023Jun 30, 2023$684.90M-15.2%
Q1 FY2023Mar 31, 2023$719.87M+29.0%
Q4 FY2022Dec 31, 2022$754.15M+31.8%
Q3 FY2022Sep 30, 2022$775.81M+193.5%
Q2 FY2022Jun 30, 2022$807.38M+193.9%
Q1 FY2022Mar 31, 2022$558.06M+92.0%
Q4 FY2021Dec 31, 2021$572.01M+202.4%
Q3 FY2021Sep 30, 2021$264.35M+32.8%
Q2 FY2021Jun 30, 2021$274.71M+30.4%
Q1 FY2021Mar 31, 2021$290.67M+22.6%
Q4 FY2020Dec 31, 2020$189.19M+28.1%
Q3 FY2020Sep 30, 2020$199.13M+101.3%
Q2 FY2020Jun 30, 2020$210.68M+99.0%
Q1 FY2020Mar 31, 2020$237.04M+106.9%
Q4 FY2019Dec 31, 2019$147.70M+20.6%
Q3 FY2019Sep 30, 2019$98.90M-24.2%
Q2 FY2019Jun 30, 2019$105.89M+61.8%
Q1 FY2019Mar 31, 2019$114.55M+203.3%
Q4 FY2018Dec 31, 2018$122.43M+165.4%
Q3 FY2018Sep 30, 2018$130.46M+181.4%
Q2 FY2018Jun 30, 2018$65.44M+20.7%
Q1 FY2018Mar 31, 2018$37.76M-37.9%
Q4 FY2017Dec 31, 2017$46.12M-31.7%
Q3 FY2017Sep 30, 2017$46.36M-36.8%
Q2 FY2017Jun 30, 2017$54.23M–
Q1 FY2017Mar 31, 2017$60.79M–
Q4 FY2016Dec 31, 2016$67.49M–
Q3 FY2016Sep 30, 2016$73.37M–

More Xenon Pharmaceuticals figures

See a number that looks wrong?